Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

A randomized phase II study of autologous cytokine-induced killer cells in treatment of hepatocellular carcinoma.

Yu X, Zhao H, Liu L, Cao S, Ren B, Zhang N, An X, Yu J, Li H, Ren X.

J Clin Immunol. 2014 Feb;34(2):194-203. doi: 10.1007/s10875-013-9976-0. Epub 2013 Dec 15.

PMID:
24337625
2.

Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma.

Lee JH, Lee JH, Lim YS, Yeon JE, Song TJ, Yu SJ, Gwak GY, Kim KM, Kim YJ, Lee JW, Yoon JH.

Gastroenterology. 2015 Jun;148(7):1383-91.e6. doi: 10.1053/j.gastro.2015.02.055. Epub 2015 Mar 4.

3.

The efficacy of cytokine-induced killer cell infusion as an adjuvant therapy for postoperative hepatocellular carcinoma patients.

Pan K, Li YQ, Wang W, Xu L, Zhang YJ, Zheng HX, Zhao JJ, Qiu HJ, Weng DS, Li JJ, Wang QJ, Huang LX, He J, Chen SP, Ke ML, Wu PH, Chen MS, Li SP, Xia JC, Zeng YX.

Ann Surg Oncol. 2013 Dec;20(13):4305-11. doi: 10.1245/s10434-013-3144-x. Epub 2013 Jul 27.

PMID:
23892527
4.

Intraperitoneal perfusion of cytokine-induced killer cells with local hyperthermia for advanced hepatocellular carcinoma.

Wang XP, Xu M, Gao HF, Zhao JF, Xu KC.

World J Gastroenterol. 2013 May 21;19(19):2956-62. doi: 10.3748/wjg.v19.i19.2956.

5.

A nomogram for predicting the benefit of adjuvant cytokine-induced killer cell immunotherapy in patients with hepatocellular carcinoma.

Pan QZ, Wang QJ, Dan JQ, Pan K, Li YQ, Zhang YJ, Zhao JJ, Weng DS, Tang Y, Huang LX, He J, Chen SP, Ke ML, Chen MS, Wicha MS, Chang AE, Zeng YX, Li Q, Xia JC.

Sci Rep. 2015 Mar 17;5:9202. doi: 10.1038/srep09202.

6.
8.

A randomized, controlled trial of postoperative adjuvant cytokine-induced killer cells immunotherapy after radical resection of hepatocellular carcinoma.

Hui D, Qiang L, Jian W, Ti Z, Da-Lu K.

Dig Liver Dis. 2009 Jan;41(1):36-41. doi: 10.1016/j.dld.2008.04.007. Epub 2008 Sep 25.

PMID:
18818130
9.

Cytokine-induced killer cells in combination with transcatheter arterial chemoembolization and radiofrequency ablation for hepatocellular carcinoma patients.

Huang ZM, Li W, Li S, Gao F, Zhou QM, Wu FM, He N, Pan CC, Xia JC, Wu PH, Zhao M.

J Immunother. 2013 Jun;36(5):287-93. doi: 10.1097/CJI.0b013e3182948452.

PMID:
23719239
10.

Dendritic Cell Immunotherapy Combined with Cytokine-Induced Killer Cells Effectively Suppresses Established Hepatocellular Carcinomas in Mice.

Jung NC, Lee JH, Choi HJ, Hwang SU, Song JY, Seo HG, Choi J, Jung SY, Han SG, Lim DS.

Immunol Invest. 2016 Aug;45(6):553-65. doi: 10.1080/08820139.2016.1183025. Epub 2016 Jul 13.

PMID:
27410037
11.

Adjuvant Cytokine-Induced Killer Cell Therapy Improves Disease-Free and Overall Survival in Solitary and Nonmicrovascular Invasive Hepatocellular Carcinoma After Curative Resection.

Chen JL, Lao XM, Lin XJ, Xu L, Cui BK, Wang J, Lin GH, Shuang ZY, Mao YZ, Huang X, Yun JP, Jin JT, Li SP.

Medicine (Baltimore). 2016 Feb;95(5):e2665. doi: 10.1097/MD.0000000000002665. Erratum in: Medicine (Baltimore). 2016 Apr;95(15):e973b.

12.

Randomized study of autologous cytokine-induced killer cell immunotherapy in metastatic renal carcinoma.

Liu L, Zhang W, Qi X, Li H, Yu J, Wei S, Hao X, Ren X.

Clin Cancer Res. 2012 Mar 15;18(6):1751-9. doi: 10.1158/1078-0432.CCR-11-2442. Epub 2012 Jan 24.

13.

Efficacy of cytokine-induced killer cell infusion as an adjuvant immunotherapy for hepatocellular carcinoma: a systematic review and meta-analysis.

Yu R, Yang B, Chi X, Cai L, Liu C, Yang L, Wang X, He P, Lu X.

Drug Des Devel Ther. 2017 Mar 17;11:851-864. doi: 10.2147/DDDT.S124399. eCollection 2017. Review.

14.

Synergistic effect of cytokine-induced killer cell with valproate inhibits growth of hepatocellular carcinoma cell in a mouse model.

Lee DH, Nam JY, Chang Y, Cho H, Kang SH, Cho YY, Cho E, Lee JH, Yu SJ, Kim YJ, Yoon JH.

Cancer Biol Ther. 2017 Jan 2;18(1):67-75. doi: 10.1080/15384047.2016.1276132.

15.

Autologous cytokine-induced killer cell immunotherapy in lung cancer: a phase II clinical study.

Li R, Wang C, Liu L, Du C, Cao S, Yu J, Wang SE, Hao X, Ren X, Li H.

Cancer Immunol Immunother. 2012 Nov;61(11):2125-33. doi: 10.1007/s00262-012-1260-2. Epub 2012 May 13.

PMID:
22581306
16.

Antitumor activities of human autologous cytokine-induced killer (CIK) cells against hepatocellular carcinoma cells in vitro and in vivo.

Wang FS, Liu MX, Zhang B, Shi M, Lei ZY, Sun WB, Du QY, Chen JM.

World J Gastroenterol. 2002 Jun;8(3):464-8.

17.

[In vitro cytotox icity effects of cocultured DC-C IK cells combined with sorafenib against hepa to cellular carcinoma].

Zhang D, He JT.

Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2011 Jun;27(6):664-7. Chinese.

PMID:
21651871
18.

Development of Hong Kong Liver Cancer staging system with treatment stratification for patients with hepatocellular carcinoma.

Yau T, Tang VY, Yao TJ, Fan ST, Lo CM, Poon RT.

Gastroenterology. 2014 Jun;146(7):1691-700.e3. doi: 10.1053/j.gastro.2014.02.032. Epub 2014 Feb 25.

PMID:
24583061
19.

Combination of radiofrequency ablation and sequential cellular immunotherapy improves progression-free survival for patients with hepatocellular carcinoma.

Cui J, Wang N, Zhao H, Jin H, Wang G, Niu C, Terunuma H, He H, Li W.

Int J Cancer. 2014 Jan 15;134(2):342-51. doi: 10.1002/ijc.28372. Epub 2013 Aug 5.

20.

CXCL17 expression predicts poor prognosis and correlates with adverse immune infiltration in hepatocellular carcinoma.

Li L, Yan J, Xu J, Liu CQ, Zhen ZJ, Chen HW, Ji Y, Wu ZP, Hu JY, Zheng L, Lau WY.

PLoS One. 2014 Oct 10;9(10):e110064. doi: 10.1371/journal.pone.0110064. eCollection 2014.

Supplemental Content

Support Center